Rosemont Pharmaceuticals
John Denman is an accomplished executive with extensive experience in the pharmaceutical industry. Currently serving as an Executive at Rosemont Pharmaceuticals since July 2023, Denman previously held influential leadership roles, including President & CEO at Avet Pharmaceuticals from April 2018 to May 2022 and CEO of the Sterile Division at Renaissance Lakewood, LLC from March 2016 to December 2017. Additionally, Denman was the General Manager for the US at Renaissance Pharma, Inc. from June 2012 to March 2016 and served as Sr. Vice President of Commercial Operations at Teva Pharmaceuticals from December 2010 to May 2012. Denman holds a Bachelor of Science in Pharmacy from Rutgers College of Pharmacy and a Juris Doctor from Widener University Schools of Law.
This person is not in any teams
This person is not in any offices
Rosemont Pharmaceuticals
At Rosemont our mission is to be a rapid developer, reliable manufacturer and global supplier of novel-delivery, patient-focused medicines. Our ambition has always been to support both patients with swallowing difficulties and the healthcare professionals who care for them. We are highly respected in the industry and have been instrumental in establishing best practice for the care of patients with swallowing difficulties. Rosemont advocate the use of liquid medication over manipulating solid dose medications and we have a range of educational materials designed for healthcare professionals which focuses on key patient groups and their medication management challenges. At Rosemont we have a portfolio of over 130 oral liquid medicines across a range of therapeutic areas including 70 licensed products. All of our products, both licensed and ‘specials’ are made to the same exacting standards under GMP. Our UK range also includes 9 products licensed for use with PEG/NG tubes. We are always seeking to expand our range of medicines and covert our ‘specials’ to licensed product wherever possible.